Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Agalimmune Founded to Develop Immunotherapeutics for Cancer

Published: Tuesday, December 03, 2013
Last Updated: Monday, December 02, 2013
Bookmark and Share
Funding will be used to continue the translation of Alphaject™ licensed from UMMS.

Agalimmune Ltd has been created to develop innovative immunotherapeutics for the treatment of cancer, with a focus on solid tumours.

The new company has been founded by an investment group comprising Loxbridge Research LLP and Animatrix Capital LLP.

Agalimmune is based both in London (Agalimmune Ltd) and California (Agalimmune Inc.). The funding will be used to continue the translation of Agalimmune’s leading immunotherapeutic technology, Alphaject™, licensed from the University of Massachusetts Medical School (UMMS), to the clinic.

Alphaject is based on over 20 years of biomedical research carried out by UMMS Professor of Surgery and Medicine Uri Galili, PhD, who discovered the anti-gal immune response and its role in ‘hyper-acute’ organ rejection.

The Alphaject technology includes methods for treating solid tumours in such a way that the immune system actively rejects them, akin to a non-matched graft or transplant. Tumours are directly injected with the Alphaject compound, to which humans naturally have a high antibody titre.

Alphaject coats the tumour cells in alphagal, thereby presenting a foreign antigen to the immune system. This is thought to bring about a 'hyper-acute rejection' of the tumour, and breaks the immune tolerance shielding the tumour from attack, allowing the immune system to both begin to destroy the tumour immediately and also to confer a long-lasting protection over time in the form of enhanced immune surveillance. The effect is analogous to a personalized cancer vaccine, acting continuously to prevent both metastasis and recurrence.

Mike Westby, CEO of Agalimmune, commented: “The development of immunomodulatory therapies is an exciting and rapidly emerging field, which hopefully will lead to improved anti-cancer treatments for patients. We welcome Loxbridge Research and Animatrix Capital as investors.”

Dr Charles Roberts, MD, CEO of Loxbridge Research, said: "Agalimmune is the first therapeutic investment we have made at a stage when the technology has already been in patients, and we are honoured to be working with proven innovators UMass Medical School and Dr Galili, in furthering this promising treatment toward the eventual benefit of people battling cancer. The investment we are making in the technology represents an upper mid-size in our portfolio, and whilst it will follow our investment model in general we are delighted to welcome in a dedicated and industry-experienced team from the outset, given the relatively late stage of the technology."

“Immunotherapy holds great promise as a potential cancer treatment because it allows the body’s own immune system to identify and eradicate cancer cells,” said Giles Whalen, MD, professor of surgical oncology at UMass Medical School and principal investigator on early clinical trials to develop the Alphaject technology. “One of the great benefits of this approach is that the immune system can seek out and attack even the smallest traces of tumour anywhere in the body. What makes Alphaject so remarkable is that it’s designed to alert the immune system and respond to a specific type of cancer cell. Unlike other immunomodulatory therapies, which may stimulate the immune system to attack cells indiscriminately, this helps ensure healthy cells don’t get mistakenly targeted and destroyed.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agalimmune Licenses KODE Biotech’s FSL Technology
Deal worth up to $31M USD (£21 million GBP).
Friday, June 19, 2015
Scientific News
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Five New Genetic Variants Linked to Brain Cancer Identified
The biggest ever study of DNA from people with glioma – the most common form of brain cancer – has discovered five new genetic variants associated with the disease.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Fatty Liver Disease and Scarring Have Strong Genetic Component
Researchers say that hepatic fibrosis, which involves scarring of the liver that can result in dysfunction and, in severe cases, cirrhosis and cancer, may be as much a consequence of genetics as environmental factors.
Specific Variations in RNA Splicing Linked to Breast Cancer
Researchers have identified cellular changes that may play a role in converting normal breast cells into tumors. Targeting these changes could potentially lead to therapies for some forms of breast cancer.
Finding Links and Missing Genes
A catalogue of large-scale genetic changes around the world.
Scientists Test New Gene Therapy for Vision Loss from a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Gene Expression: A Snapshot of Stem Cell Development
New genes found that regulate development of stem cells.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
A Natural History of Neurons
Diverse mutations reveal lineage of brain cells.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos